924 related articles for article (PubMed ID: 27321965)
1. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
Shepshelovich D; Rozen-Zvi B; Avni T; Gafter U; Gafter-Gvili A
Am J Kidney Dis; 2016 Nov; 68(5):677-690. PubMed ID: 27321965
[TBL] [Abstract][Full Text] [Related]
2. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis.
Rozen-Zvi B; Gafter-Gvili A; Paul M; Leibovici L; Shpilberg O; Gafter U
Am J Kidney Dis; 2008 Nov; 52(5):897-906. PubMed ID: 18845368
[TBL] [Abstract][Full Text] [Related]
3. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
4. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
Albaramki J; Hodson EM; Craig JC; Webster AC
Cochrane Database Syst Rev; 2012 Jan; 1():CD007857. PubMed ID: 22258974
[TBL] [Abstract][Full Text] [Related]
5. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
6. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
7. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
9. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
10. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD.
Van Wyck DB; Roppolo M; Martinez CO; Mazey RM; McMurray S;
Kidney Int; 2005 Dec; 68(6):2846-56. PubMed ID: 16316362
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
Romanet T; Bedouch P; Zaoui P
Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
[TBL] [Abstract][Full Text] [Related]
13. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.
Pisani A; Riccio E; Sabbatini M; Andreucci M; Del Rio A; Visciano B
Nephrol Dial Transplant; 2015 Apr; 30(4):645-52. PubMed ID: 25395392
[TBL] [Abstract][Full Text] [Related]
15. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
16. Iron Deficiency Anemia in Chronic Kidney Disease.
Gafter-Gvili A; Schechter A; Rozen-Zvi B
Acta Haematol; 2019; 142(1):44-50. PubMed ID: 30970355
[TBL] [Abstract][Full Text] [Related]
17. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
Spinowitz B; Pecoits-Filho R; Winkelmayer WC; Pergola PE; Rochette S; Thompson-Leduc P; Lefebvre P; Shafai G; Bozas A; Sanon M; Krasa HB
J Med Econ; 2019 Jun; 22(6):593-604. PubMed ID: 30813807
[No Abstract] [Full Text] [Related]
18. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]